Hypercholesterolaemic effect of fish oil in insulin-dependent diabetic patients

R Vandongen, Trevor Mori, J P Codde, K G Stanton, J R Masarei

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The effect of the daily administration of Max EPA fish oil (equivalent to 2.7 g per day of eicosapentaenoic acid) on serum lipid levels was examined in insulin-dependent male diabetic patients with cholesterol levels of less than 6.5 mmol/L. After three weeks of fish-oil supplementation there was a significant rise in total cholesterol levels, which was due largely to increases in low-density lipoprotein (LDL)- and high-density lipoprotein (HDL)- cholesterol levels. The increase in HDL-cholesterol levels was accounted for by its HDL2 subclass. There was a decrease in serum triglyceride levels, but this was also observed in a control group of diabetic patients who did not receive fish oil and is probably explained by weight loss in this group. Similar changes in lipid levels were found in a subgroup of diabetic patients with retinopathy. The possible detrimental effect of the increase in total cholesterol and LDL-cholesterol levels after Max EPA fish oil at this dose may be offset by the selective rise in the protective HDL2 subclass.

Original languageEnglish
Pages (from-to)141-3
Number of pages3
JournalThe Medical journal of Australia
Volume148
Issue number3
Publication statusPublished - 1 Feb 1988

Fingerprint

Fish Oils
Insulin
Cholesterol
HDL Cholesterol
Lipids
Eicosapentaenoic Acid
Serum
LDL Lipoproteins
LDL Cholesterol
Weight Loss
Triglycerides
Control Groups
Maxepa

Cite this

@article{cc6dbfdc5a054bccbfe085ce6b68d878,
title = "Hypercholesterolaemic effect of fish oil in insulin-dependent diabetic patients",
abstract = "The effect of the daily administration of Max EPA fish oil (equivalent to 2.7 g per day of eicosapentaenoic acid) on serum lipid levels was examined in insulin-dependent male diabetic patients with cholesterol levels of less than 6.5 mmol/L. After three weeks of fish-oil supplementation there was a significant rise in total cholesterol levels, which was due largely to increases in low-density lipoprotein (LDL)- and high-density lipoprotein (HDL)- cholesterol levels. The increase in HDL-cholesterol levels was accounted for by its HDL2 subclass. There was a decrease in serum triglyceride levels, but this was also observed in a control group of diabetic patients who did not receive fish oil and is probably explained by weight loss in this group. Similar changes in lipid levels were found in a subgroup of diabetic patients with retinopathy. The possible detrimental effect of the increase in total cholesterol and LDL-cholesterol levels after Max EPA fish oil at this dose may be offset by the selective rise in the protective HDL2 subclass.",
keywords = "Adult, Cholesterol, HDL, Cholesterol, LDL, Diabetes Mellitus, Type 1, Diet, Docosahexaenoic Acids, Drug Combinations, Eicosapentaenoic Acid, Fatty Acids, Unsaturated, Fish Oils, Humans, Lipids, Lipoproteins, HDL, Lipoproteins, HDL2, Lipoproteins, HDL3, Male, Triglycerides, Journal Article, Research Support, Non-U.S. Gov't",
author = "R Vandongen and Trevor Mori and Codde, {J P} and Stanton, {K G} and Masarei, {J R}",
year = "1988",
month = "2",
day = "1",
language = "English",
volume = "148",
pages = "141--3",
journal = "Medical Journal Australia",
issn = "0025-729X",
publisher = "Australasian Medical Publishing Co. Ltd",
number = "3",

}

Hypercholesterolaemic effect of fish oil in insulin-dependent diabetic patients. / Vandongen, R; Mori, Trevor; Codde, J P; Stanton, K G; Masarei, J R.

In: The Medical journal of Australia, Vol. 148, No. 3, 01.02.1988, p. 141-3.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hypercholesterolaemic effect of fish oil in insulin-dependent diabetic patients

AU - Vandongen, R

AU - Mori, Trevor

AU - Codde, J P

AU - Stanton, K G

AU - Masarei, J R

PY - 1988/2/1

Y1 - 1988/2/1

N2 - The effect of the daily administration of Max EPA fish oil (equivalent to 2.7 g per day of eicosapentaenoic acid) on serum lipid levels was examined in insulin-dependent male diabetic patients with cholesterol levels of less than 6.5 mmol/L. After three weeks of fish-oil supplementation there was a significant rise in total cholesterol levels, which was due largely to increases in low-density lipoprotein (LDL)- and high-density lipoprotein (HDL)- cholesterol levels. The increase in HDL-cholesterol levels was accounted for by its HDL2 subclass. There was a decrease in serum triglyceride levels, but this was also observed in a control group of diabetic patients who did not receive fish oil and is probably explained by weight loss in this group. Similar changes in lipid levels were found in a subgroup of diabetic patients with retinopathy. The possible detrimental effect of the increase in total cholesterol and LDL-cholesterol levels after Max EPA fish oil at this dose may be offset by the selective rise in the protective HDL2 subclass.

AB - The effect of the daily administration of Max EPA fish oil (equivalent to 2.7 g per day of eicosapentaenoic acid) on serum lipid levels was examined in insulin-dependent male diabetic patients with cholesterol levels of less than 6.5 mmol/L. After three weeks of fish-oil supplementation there was a significant rise in total cholesterol levels, which was due largely to increases in low-density lipoprotein (LDL)- and high-density lipoprotein (HDL)- cholesterol levels. The increase in HDL-cholesterol levels was accounted for by its HDL2 subclass. There was a decrease in serum triglyceride levels, but this was also observed in a control group of diabetic patients who did not receive fish oil and is probably explained by weight loss in this group. Similar changes in lipid levels were found in a subgroup of diabetic patients with retinopathy. The possible detrimental effect of the increase in total cholesterol and LDL-cholesterol levels after Max EPA fish oil at this dose may be offset by the selective rise in the protective HDL2 subclass.

KW - Adult

KW - Cholesterol, HDL

KW - Cholesterol, LDL

KW - Diabetes Mellitus, Type 1

KW - Diet

KW - Docosahexaenoic Acids

KW - Drug Combinations

KW - Eicosapentaenoic Acid

KW - Fatty Acids, Unsaturated

KW - Fish Oils

KW - Humans

KW - Lipids

KW - Lipoproteins, HDL

KW - Lipoproteins, HDL2

KW - Lipoproteins, HDL3

KW - Male

KW - Triglycerides

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

M3 - Article

VL - 148

SP - 141

EP - 143

JO - Medical Journal Australia

JF - Medical Journal Australia

SN - 0025-729X

IS - 3

ER -